Erasca, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Erasca priced 31.4M shares at $17.50/share (gross proceeds ~$550M) on July 13, 2026, with underwriters (JPMorgan, Morgan Stanley, Jefferies, Evercore) holding a 30-day option for 4.7M additional shares. Proceeds to fund R&D and general corporate purposes. Closing expected July 15, 2026.
Why this rating
Large capital raise (~$550M gross = 174% of $316M market cap) strengthens balance sheet for clinical development; meaningful dilution but typical for biotech. Moderate materiality given company size and clinical-stage status.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.